ArticleAnnals of surgical oncology2026
UCHL1 Maintains MUC3A Stability through Deubiquitination to Activate the Downstream Pathways of EGFR, Driving Proliferation and Epithelial-Mesenchymal Transition in Extrahepatic Cholangiocarcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Refining Patient Selection for Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiotherapy in Rectal Cancer.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMUC3A is upregulated in the serum of patients with extrahepatic cholangiocarcinoma (EHCC). Nevertheless, the specific role of MUC3A in EHCC is elusive. Therefore, this study aimed to analyze the role and mechanism of MUC3A in cell proliferation and epithelial-mesenchymal transition (EMT) in EHCC. MATERIALS AND
methodsUCHL1 and MUC3A expression levels were measured in EHCC cells and tissues. After gain- and loss-of-function assays in EHCC cells, cell proliferation was assessed with CCK-8, EdU, and colony formation assays, while cell invasion, migration, and apoptosis were examined with transwell, scratch, and flow cytometry assays, respectively. Western blot was implemented to detect the levels of migration- and EMT-related markers, as well as proteins related to the downstream pathways of EGFR. A xenograft tumor model was established for in vitro validation. The relationship between UCHL1 and MUC3A was analyzed with Co-immunoprecipitation (Co-IP), Western blotting, ubiquitination analysis, and immunofluorescence.
resultsUCHL1 and MUC3A were highly expressed in EHCC. MUC3A knockdown inhibited the viability, EMT, migration, and invasion of ECHH cells while accelerating their apoptosis. MUC3A knockdown repressed tumorigenesis of EHCC in mice. Mechanistically, UCHL1 acted as a deubiquitinase to maintain MUC3A stability and activated the downstream pathways of EGFR, namely Ras/Raf/MEK/ERK and PI3K/AKT. UCHL1 overexpression nullified the repressive impacts of MUC3A knockdown on EHCC cell viability, invasion, and EMT, while EGFR activation abrogated the suppressive impacts of UCHL1 depletion on EHCC cell viability, invasion, and EMT.
conclusionsUCHL1 activates downstream pathways of EGFR by stabilizing MUC3A, thereby fostering EHCC progression.
Indexed as
Identifiers
41145942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.